PLSE — Pulse Biosciences Inc
NASDAQ · Healthcare · Medical Instruments & Supplies
$52.09
+$1.76 (+3.50%)
Pulse Biosciences Inc (PLSE) is a medical instruments & supplies company listed on NASDAQ. It is led by Paul Arthur LaViolette, based in 601 Brickell Key Drive, Miami, FL, United States, 33131, with about 75 employees. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Latest reported PLSE revenue for 2025-09-30 was $86.0K. Net income was -$19.4M. PLSE currently screens at market cap $1.03B.
Use this PLSE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PLSE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PLSE SEC filings page. Lician reads the product cache first so this HTML stays unique to Pulse Biosciences Inc even when a live quote feed is slow.
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
PLSE Key Statistics
Market Cap
$1.03B
Volume
366,502
Previous Close
$49.13
Day Range
$47.65 – $50.90
EPS
$0.00
Revenue
$0.00
Net Income
-$53.59M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
75
PLSE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $700.00K | $1.42M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$53.59M | -$42.21M | -$58.51M | -$63.66M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$132.46M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$118.04M
Operating Cash Flow
-$36.34M
Free Cash Flow
$0.00
Pulse Biosciences Inc Company Information
- President, CEO, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board
- Paul Arthur LaViolette
- Headquarters
- 601 Brickell Key Drive, Miami, FL, United States, 33131
- Website
- www.pulsebiosciences.com
- Phone
- 510 906 4600
- IPO / Founded
- 2016-05-18
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies